Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06126406
What this trial is testing

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Who this might be right for
Gastric CancerColon CancerRectal Cancer+5 more
Chongqing Precision Biotech Co., Ltd 60
Early research (Phase 1)Study completedNCT03244306
What this trial is testing

CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma

Who this might be right for
Leukemia
Seattle Children's Hospital 4
Not applicableUnknownNCT06727383
What this trial is testing

CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors

Who this might be right for
Healthy DonorsMyeloproliferative DiseasesLymphoproliferative Disorders
European Institute of Oncology 140
Early research (Phase 1)Ended earlyNCT02465983
What this trial is testing

Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
University of Pennsylvania 4
Early research (Phase 1)Ended earlyNCT05128786
What this trial is testing

CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

Who this might be right for
SAR
Shanghai PerHum Therapeutics Co., Ltd. 9
Early research (Phase 1)Looking for participantsNCT02917083
What this trial is testing

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Who this might be right for
Hodgkin's LymphomaNon-Hodgkin Lymphoma
Baylor College of Medicine 60
Early research (Phase 1)Looking for participantsNCT07233642
What this trial is testing

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Who this might be right for
Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine 18
Testing effectiveness (Phase 2)Study completedNCT04205409
What this trial is testing

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more
University of Washington 20
Testing effectiveness (Phase 2)Looking for participantsNCT06364423
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellB-Lymphocytic Leukemia, ChronicB-Cell Chronic Lymphocytic Leukemia+4 more
National Cancer Institute (NCI) 132
Testing effectiveness (Phase 2)UnknownNCT05381662
What this trial is testing

CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Who this might be right for
Acute Lymphoblastic Leukemia in Remission
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 10
Early research (Phase 1)Looking for participantsNCT05528341
What this trial is testing

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Who this might be right for
Relapsed/Refractory Solid Tumors
Henan Medical University 20
Early research (Phase 1)UnknownNCT03344705
What this trial is testing

Safety and Efficacy Evaluation of IM19 Cells

Who this might be right for
Hematological Malignancies
Beijing Immunochina Medical Science & Technology Co., Ltd. 20
Post-approval studies (Phase 4)Study completedNCT05108805
What this trial is testing

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Who this might be right for
Large B-cell LymphomaDiffuse Large B-cell Lymphoma
Vanderbilt-Ingram Cancer Center 25
Early research (Phase 1)UnknownNCT05528887
What this trial is testing

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Who this might be right for
Relapsed/Refractory Hematological MalignanciesLymphomaMyeloma+1 more
The Affiliated People's Hospital of Ningbo University 10
Early research (Phase 1)UnknownNCT02915445
What this trial is testing

EpCAM CAR-T for Treatment of Advanced Solid Tumors

Who this might be right for
Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)Breast Cancer RecurrentGastric Cancer With Metastasis
Sichuan University 30
Not applicableUnknownNCT06142175
What this trial is testing

Relmacabtagene Autoleucel in Patients With LBCL

Who this might be right for
Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 200
Not applicableStudy completedNCT06415656
What this trial is testing

VitalTraq for the Detection of CRS

Who this might be right for
Hematologic Malignancy
Duke University 32
Early research (Phase 1)Ended earlyNCT04160195
What this trial is testing

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Non-hodgkinsChronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI) 2
Not applicableNot Yet RecruitingNCT07345780
What this trial is testing

Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies

Who this might be right for
CD7-Positive Hematological Malignancies
Donghua Zhang 28
Testing effectiveness (Phase 2)Looking for participantsNCT05905328
What this trial is testing

Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy

Who this might be right for
Cytokine Release Syndrome
CytoAgents, Inc. 54
Next Page